Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits

Neurochemical Research

Volumn 28, Issue 2, 2003, Pages 235-241

  Schmitt, Andrea ^a   Zink, Mathias ^a   Müller, Bettina ^a   May, Brigitte ^a   Herb, Anne ^b   Jatzko, Alexander ^a   Braus, Dieter F ^a   Henn, Fritz A ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clozapine; Gene expression; Haloperidol; NMDA receptor; NMDA subunits; Receptor autoradiography

Indexed keywords

CLOZAPINE; DIZOCILPINE; DRINKING WATER; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PROTEIN SUBUNIT; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; DRUG EFFECT; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENETIC ANALYSIS; IN SITU HYBRIDIZATION; LONG TERM CARE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; UPREGULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; CLOZAPINE; GENE EXPRESSION; HALOPERIDOL; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

ANIMALIA;

EID: 0037321715     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022325116309     Document Type: Article

References (51)

1. Jentsch, J. D. and Roth, R. H. 1999. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
2. Javitt, D. C. and Zukin, S. R. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148:1301-1308.
3. Olney, J. W. and Farber, N. B. 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52:998-1007.
4. Farber, N. B., Newcomer, J. W., and Olney, J. W. 1999. Glycine agonists: What can they teach us about schizophrenia? Arch. Gen. Psychiatry 56:13-17.
5. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., and Seeburg, P. H. 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
6. Ishii, T., Moriyoshi, K., Sugihara, H., Sakurada, K., Kadotani, H., Yokoi, M., Akazawa, C., Shigemoto, R., Mizuno, N., and Masu, M. 1993. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J. Biol. Chem. 268:2836-2843.
7. Aparicio-Legarza, M. I., Davis, B., Hutson, P. H., and Reynolds, G. P. 1998. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci. Lett. 241:143-146.
8. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural Transm. 77:231-236.
9. Noga, J. T., Hyde, T. M., Herman, M. M., Spurney, C. F., Bigelow, L. B., Weinberger, D. R., and Kleinman, J. E. 1997. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 27:168-176.
10. Grimwood, S., Slater, P., Deakin, J. F., and Hutson, P. H. 1999. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 10:461-465.
11. Dean, B., Scarr, E., Bradbury, R., and Copolov, D. 1999. Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Synapse 32:67-69.
12. Sokolov, B. P. 1998. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 71:2454-2464.
13. Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., and Tamminga, C. A. 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. Am. J. Psychiatry 157:1141-1149.
14. Humphries, C., Mortimer, A., Hirsch, S., and de Belleroche, J. 1996. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7:2051-2055.
15. Akbarian, S., Sucher, N. J., Bradley, D., Tafazzoli, A., Trinh, D., Hetrick, W. P., Potkin, S. G., Sandman, C. A., Bunney, W. E., Jr., and Jones, E. G. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16:19-30.
16. 3H]MK801-binding sites in the rat brain: A side-preference action in cortical areas. Brain Res. 762:216-218.
17. Tarazi, F. I., Florijn, W. J., and Creese, I. 1996. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128:371-379.
18. McCoy, L. and Richfield, E. K. 1996. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett. 213:137-141.
19. Spumey, C. F., Baca, S. M., Murray, A. M., Jaskiw, G. E., Kleinman, J. E., and Hyde, T. M. 1999. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34:266-276.
20. Banerjee, S. P., Zuck, L. G., Yablonsky-Alter, E., and Lidsky, T. I. 1995. Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport 6:2500-2504.
21. Ossowska, K., Pietraszek, M., Wardas, J., Nowak, G., and Wolfarth, S. 1999. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs Arch. Pharmacol. 359:280-287.
22. Meshul, C. K., Bunker G. L., Mason J. N., Allen C., and Janowsky A. 1996. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem. 67:1965-1973.
23. Fitzgerald, L. W., Deutch, A. Y., Gasic, G., Heinemann, S. F., and Nestler, E. J. 1995. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15:2453-2461.
24. Riva, M. A., Tascedda, F., Lovati, E., and Racagni, G. 1997. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res. Mol. Brain Res. 50:136-142.
25. Tascedda, F., Lovati, E., Blom, J. M., Muzzioli, P., Brunello, N., Racagni, G., and Riva, M. A. 1999. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21:211-217.
26. See, R. E. and Ellison, G. 1990. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur. J. Pharmacol. 181:175-186.
27. Volavka, J., Cooper, T., Czobor, P., Bitter, I., Meisner, M., Laska, E., Gastanaga, P., Krakowski, M., Chou, J. C., and Crowner, M. 1992. Haloperidol blood levels and clinical effects. Arch. Gen. Psychiatry. 49:354-361.
28. Zilles, K. and Schleicher, A. 1995. Correlative imaging of transmitter receptor distributions in human cortex. Pages 277-307, in Stumpf W. E. and Solomon H. F. (eds.), Autoradiography and Correlative Imaging, Academic Press, San Diego.
29. Zilles, K., Qu, M. S., Kohling, R., and Speckmann, E. J. 1999. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: Quantitative in vitro receptor autoradiography. Neuroscience 94:1051-1061.
30. 3H]MK-801 binding in rat brain. Brain Res. 710:103-111.
31. Floresco, S. B., Blaha, C. D., Yang, C. R., and Phillips, A. G. 2001. Dopamine D1 and NMDA receptors mediate potentiation of basolateral amygdala-evoked firing of nucleus accumbens neurons. J. Neurosci. 21:6370-6376.
32. Swerdlow, N. R., Hanlon, F. M., Henning, L., Kim, Y. K., Gaudet, I., and Halim, N. D. 2001. Regulation of sensorimotor gating in rats by hippocampal NMDA: Anatomical localization. Brain Res. 898:195-203.
33. Yamamoto, B. K., Pehek, E. A., and Meltzer, H. Y. 1994. Brain region effects of clozapine on amino acid and monoamine transmission. J. Clin. Psychiatry. 55(Suppl B):8-14.
34. Lipton, S. A. and Kater, S. B. 1989. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurosci. 12:265-270.
35. Kerns, J. M., Sierens, D. K., Kao, L. C., Klawans, H. L., and Carvey, P. M. 1992. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin. Neuropharmacol. 15:488-500.
36. Meshul, C. K., Buckman, J. F., Allen, C., Riggan, J. P., and Feller, D. J. 1996. Activation of corticostriatal pathway leads to similar morphological changes observed following haloperidol treatment. Synapse 22:350-361.
37. Meshul, C. K., Stallbaumer, R. K., Taylor, B., and Janowsky, A. 1994. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648:181-195.
38. See, R. E. and Chapman, M. A. 1994. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol. 263:269-276.
39. Oretti, R. G., Spurlock, G., Buckland, P. R., and McGuffin, P. 1994. Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains. Neurosci. Lett. 177:39-43.
40. Chen, A. C., McDonald, B., Moss, S. J., and Gurling, H. M. 1998. Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment. Brain Res. Mol. Brain Res. 54:92-100.
41. Morikawa, E., Mori, H., Kiyama, Y., Mishina, M., Asano, T., and Kirino, T. 1998. Attenuation of focal ischemic brain injury in mice deficient in the epsilon1 (NR2A) subunit of NMDA receptor. J. Neurosci. 18:9727-9732.
42. Tang, Y. P., Shimizu, E., Dube, G. R., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., and Tsien, J. Z. 1999. Genetic enhancement of learning and memory in mice. Nature 401:63-69.
43. Greene, R. 2001. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11:569-577.
44. Yamamoto, B. K. and Cooperman, M. A. 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:4159-4166.
45. Chen, L. and Yang, C. R. 2002. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol. 87:2324-2336.
46. Korpi, E. R., Wong, G., and Luddens, H. 1995. Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. Naunyn Schmiedebergs Arch. Pharmacol. 352: 365-373.
47. Ding, D. C., Gabbott, P. L., and Totterdell, S. 2001. Differences in the laminar origin of projections from the medial prefrontal cortex to the nucleus accumbens shell and core regions in the rat. Brain Res. 917:81-89.
48. Buchsbaum, M. S., Hazlett, E. A., Haznedar, M. M., Spiegel-Cohen, J., and Wei, T. C. 1999. Visualizing fronto-striatal circuitry and neuroleptic effects in schizophrenia. Acta Psychiatr. Scand. Suppl. 395:129-137.
49. 3H]sulpiride binding in rat caudate-putamen: Autoradiographic evidence for presynaptic D2 receptors on corticostriate terminals. Synapse 2:521-531.
50. Fletcher, E. J. and MacDonald, J. F. 1993. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur. J. Pharmacol. 235:291-295.
51. Carlsson, A., Hansson L.O., Waters, N., and Carlsson, M.L. 1997. Neurotransmitter aberrations in schizophrenia, new perspectives and therapeutic implications. Life Sci; 61:75-94.